Key Highlights

  • Net loss per share was USD 0.89, against an estimate of a USD 0.69 loss.
  • Net loss widened to USD 21.16 million from USD 6.61 million.
  • Research and development expenses rose to USD 15.02 million from USD 2.83 million.
  • Cash and cash equivalents were USD 16.34 million at September 30, 2026.

LeonaBio (NASDAQ:LONA) reported a third quarter 2026 net loss of USD 21.16 million, compared with USD 6.61 million in the prior-year quarter. Basic and diluted net loss per share attributable to common stockholders was USD 0.89, compared with USD 1.68, against an estimate of a USD 0.69 loss. No Revenue was recorded in either period, and weighted average shares used in computing net loss per share were 23,740,719, compared with 3,943,887.

Spending Behind the Loss

Research and development expenses were USD 15.02 million, compared with USD 2.83 million, and general and administrative expenses were USD 6.86 million, compared with USD 4.05 million. The change in Fair Value of a milestone Liability was a Credit of USD 411 thousand.

Total operating expenses were USD 21.47 million, compared with USD 6.87 million, and the loss from operations matched those totals in both periods. Other income, net, was USD 303 thousand, compared with USD 263 thousand. The comprehensive loss attributable to common stockholders was USD 21.17 million, which includes an unrealized loss on available-for-sale securities of USD 3 thousand.

Nine Months to September 30

For the nine months ended September 30, 2026, Research and Development expenses were USD 38.98 million, compared with USD 10.79 million, and general and administrative expenses were USD 20.32 million, compared with USD 12.91 million. The change in fair value of the milestone liability was a credit of USD 1.17 million. Total operating expenses were USD 58.13 million, compared with USD 23.70 million, and again equaled the loss from operations.

The company recorded a loss of USD 16.32 million on the change in fair value of the Sermonix pre-funded warrant. The net loss was USD 73.12 million, compared with USD 22.72 million, and net loss per share was USD 3.30, compared with USD 5.80. Weighted average shares were 22,181,938, compared with 3,919,258.

Cash, Liabilities and Going Concern Doubt

Cash and cash equivalents were USD 16.34 million at September 30, 2026, compared with USD 69.28 million at December 31, 2025, and short-term investments were USD 15.97 million, compared with USD 19.06 million. Total Assets were USD 38.14 million, compared with USD 92.15 million.

Total current liabilities were USD 7.33 million, compared with USD 47.50 million, and total liabilities were USD 22.12 million, compared with USD 64.36 million. Additional paid-in Capital was USD 600.90 million, compared with USD 539.55 million. The filing raises substantial doubt over going concern status for the period following the date of the quarterly report.